6PA1 image
Entry Detail
PDB ID:
6PA1
Keywords:
Title:
Killer cell immunoglobulin-like receptor 2DL2 in complex with HLA-C*07:02
Biological Source:
Host Organism:
PDB Version:
Deposition Date:
2019-06-11
Release Date:
2020-12-16
Method Details:
Experimental Method:
Resolution:
3.01 Å
R-Value Free:
0.30
R-Value Work:
0.26
R-Value Observed:
0.26
Space Group:
P 1 21 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:HLA class I histocompatibility antigen, Cw-7 alpha chain
Chain IDs:A, E
Chain Length:277
Number of Molecules:2
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:Beta-2-microglobulin
Chain IDs:B, F
Chain Length:100
Number of Molecules:2
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:ARG-TYR-ARG-PRO-GLY-THR-VAL-ALA-LEU
Chain IDs:C, G
Chain Length:9
Number of Molecules:2
Biological Source:synthetic construct
Polymer Type:polypeptide(L)
Description:Killer cell immunoglobulin-like receptor 2DL2
Chain IDs:D, H
Chain Length:204
Number of Molecules:2
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
Structural plasticity of KIR2DL2 and KIR2DL3 enables altered docking geometries atop HLA-C.
Nat Commun 12 2173 2173 (2021)
PMID: 33846289 DOI: 10.1038/s41467-021-22359-x

Abstact

The closely related inhibitory killer-cell immunoglobulin-like receptors (KIR), KIR2DL2 and KIR2DL3, regulate the activation of natural killer cells (NK) by interacting with the human leukocyte antigen-C1 (HLA-C1) group of molecules. KIR2DL2, KIR2DL3 and HLA-C1 are highly polymorphic, with this variation being associated with differences in the onset and progression of some human diseases. However, the molecular bases underlying these associations remain unresolved. Here, we determined the crystal structures of KIR2DL2 and KIR2DL3 in complex with HLA-C*07:02 presenting a self-epitope. KIR2DL2 differed from KIR2DL3 in docking modality over HLA-C*07:02 that correlates with variabilty of recognition of HLA-C1 allotypes. Mutagenesis assays indicated differences in the mechanism of HLA-C1 allotype recognition by KIR2DL2 and KIR2DL3. Similarly, HLA-C1 allotypes differed markedly in their capacity to inhibit activation of primary NK cells. These functional differences derive, in part, from KIR2DS2 suggesting KIR2DL2 and KIR2DL3 binding geometries combine with other factors to distinguish HLA-C1 functional recognition.

Legend

Protein

Chemical

Disease

Primary Citation of related structures